Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction

Inhibiting thrombosis is a cornerstone of vascular protection. Antiplatelet therapies, like aspirin and P2Y12 inhibitors, are used to prevent thrombosis and are widely endorsed in current clinical practice recommendations. Recent data suggest that "dual anti-thrombotic pathway inhibition" targeting platelets and coagulation may further reduce the residual atherosclerotic risk. This innovative thesis was tested in the COMPASS (Cardiovascular...